



## 2019 NEGATIVE FORMULARY CHANGE NOTICE

---

A negative formulary change is defined as any of the following changes:

- 1) removal of a drug from a formulary
- 2) increasing the cost-sharing status of a drug on the formulary subsequent to a change in tier
- 3) adding or making more restrictive utilization management requirements on a drug, including
  - a. prior authorization requirements
  - b. quantity limits
  - c. step therapy requirements

**Effective date of change: 06/01/2019**

<b>Drug name (medication)</b>	<b>Drug List (formulary) Change</b>	<b>Reason for change</b>	<b>Notes</b>
Auryxia (ferric citrate) 210 mg tabs	Utilization management addition	Prior authorization (PA) added	PA applies to new starts only

All Cigna products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company, Cigna HealthCare of South Carolina, Inc., Cigna HealthCare of North Carolina, Inc., Cigna HealthCare of Georgia, Inc., Cigna HealthCare of Arizona, Inc., Cigna HealthCare of St. Louis, Inc., HealthSpring Life & Health Insurance Company, Inc., HealthSpring of Florida, Inc., Bravo Health Mid-Atlantic, Inc., and Bravo Health Pennsylvania, Inc. The Cigna name, logos, and other Cigna marks are owned by Cigna Intellectual Property, Inc. Cigna-HealthSpring is contracted with Medicare for PDP plans, HMO and PPO plans in select states, and with select State Medicaid programs. Enrollment in Cigna-HealthSpring depends on contract renewal.